These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4113219)

  • 1. Cholinergic reversal of manic symptoms.
    Janowsky DS; el-Yousef MK; Davis JM; Hubbard B; Sekerke HJ
    Lancet; 1972 Jun; 1(7762):1236-7. PubMed ID: 4113219
    [No Abstract]   [Full Text] [Related]  

  • 2. Physostigmine in mania.
    Davis KL; Berger PA; Hollister LE; Defraites E
    Arch Gen Psychiatry; 1978 Jan; 35(1):119-22. PubMed ID: 339869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RS 86 in manic disorder.
    van Berkestijn H; van der Meulen LM; Flentge F; Dols L; van den Hoofdakker R
    Biol Psychiatry; 1990 Jan; 27(1):109-12. PubMed ID: 2404521
    [No Abstract]   [Full Text] [Related]  

  • 4. Physostigmine temporarily and dramatically reversing acute mania.
    Khouzam HR; Kissmeyer PM
    Gen Hosp Psychiatry; 1996 May; 18(3):203-4. PubMed ID: 8739014
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholinergic reversal of manic symptoms.
    Carroll BJ; Frazer A; Schless A; Mendels J
    Lancet; 1973 Feb; 1(7800):427-8. PubMed ID: 4119737
    [No Abstract]   [Full Text] [Related]  

  • 6. Rebound phenomena in manic patients following physostigmine. Preliminary observations.
    Shopsin B; Janowsky D; Davis J; Gershon S
    Neuropsychobiology; 1975; 1(3):180-7. PubMed ID: 8744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic influence on manic symptoms.
    Krieg JC; Berger M
    Clin Neuropharmacol; 1986; 9 Suppl 4():544-6. PubMed ID: 3567961
    [No Abstract]   [Full Text] [Related]  

  • 8. Learning and memory of chronic alcoholics influenced cholinotropic drugs.
    Krus D; Vojtĕchovký M; Rubes J
    Act Nerv Super (Praha); 1967 Nov; 9(4):420-1. PubMed ID: 4889078
    [No Abstract]   [Full Text] [Related]  

  • 9. Cholinergic approaches to the treatment of Alzheimer's disease.
    Hollander E; Mohs RC; Davis KL
    Br Med Bull; 1986 Jan; 42(1):97-100. PubMed ID: 3006861
    [No Abstract]   [Full Text] [Related]  

  • 10. Parasympathetic suppression of manic symptoms by physostigmine.
    Janowsky DS; el-Yousef K; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Apr; 28(4):542-7. PubMed ID: 4692153
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Rebound phenomenon in manic patients following physostigmine: towards an understanding of aminergic mechanisms underlying affective disorders.
    Shopsin B; Janowsky D; Davis J; Gershon S
    Psychopharmacol Bull; 1974 Jul; 10(3):50-1. PubMed ID: 4419431
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.
    Davis KL; Berger PA
    Biol Psychiatry; 1978 Feb; 13(1):23-49. PubMed ID: 146524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of mania with the cholinomimetic agent RS 86.
    Krieg JC; Berger M
    Br J Psychiatry; 1986 May; 148():613. PubMed ID: 3535973
    [No Abstract]   [Full Text] [Related]  

  • 14. Naloxone effects on manic symptoms and growth-hormone levels.
    Janowsky D; Judd L; Huey L; Roitman N; Parker D; Segal D
    Lancet; 1978 Aug; 2(8084):320. PubMed ID: 79114
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal by physostigmine of clozapine-induced delirium.
    Schuster P; Gabriel E; Küfferle B; Strobl G; Karobath M
    Clin Toxicol; 1977; 10(4):437-41. PubMed ID: 862378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)].
    Modestin J; Schwartz RB; Hunger J
    Pharmakopsychiatr Neuropsychopharmakol; 1973 Nov; 6(6):300-4. PubMed ID: 4603643
    [No Abstract]   [Full Text] [Related]  

  • 18. Physostigmine reversal of scopolamine-induced hypofrontality.
    Prohovnik I; Arnold SE; Smith G; Lucas LR
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):220-8. PubMed ID: 9040502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer's disease: hopes and reality.
    Gauthier S; Gauthier L; Bouchard R; Quirion R; Sultan S
    Can J Neurol Sci; 1991 Aug; 18(3 Suppl):439-41. PubMed ID: 1933695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary studies on the use of thyrotropin releasing hormone in manic states, depression, and the dysphoria of alcohol withdrawal.
    Huey LY; Janowsky DS; Mandell AJ; Judd LL; Pendery M
    Psychopharmacol Bull; 1975 Jan; 11(1):24-27. PubMed ID: 804705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.